Cancer Survivorship Training Program

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

BETHESDA, Md-In response to the difficult and complex issues affecting cancer survivors, the National Cancer Institute (NCI) has created a new training program, The Cancer Journey: Issues for Survivors. It is designed for health professionals in training roles to educate their peers about the many issues cancer survivors face.

BETHESDA, Md—In response to the difficult and complex issues affecting cancer survivors, the National Cancer Institute (NCI) has created a new training program, The Cancer Journey: Issues for Survivors. It is designed for health professionals in training roles to educate their peers about the many issues cancer survivors face.

The training program was developed by NCI’s Office of Cancer Information, Communication, and Education in collaboration with Ortho Biotech Inc., the National Coalition for Cancer Survivorship, and cancer organizations nationwide.

To obtain a free copy of the training program, please contact the NCI’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

Articles in this issue
Tobacco Companies Reach Settlement With Texas for $15.3 Billion
Archives to Collect Info on Radiation Exposure Worldwide
Few BRCA-1 Carriers Take Recommended Precautions
Lifelong Weight Control a Key to Breast Ca Prevention
Eight-Year Prostate Brachytherapy Update Shows Good Results
Patient Brochure on Breast Cancer Tumor Markers
Gay Men’s Health Crisis Calls for HIV Reporting in New York
Single-Agent Taxanes in Advanced Breast Cancer: A Commentary
ODAC Declines to Vote on DepoCyt FDA Recommendation
Photofrin Approved for Early-Stage Lung Cancer
Breast Cancer Diagnosed After Childbirth May Be More Severe
NCCN Forum: Who Pays for Clinical Trials?
AHCPR Smoking Interventions Are Cost Effective
Senator Urges Consensus on Tobacco Law
Thomas Jefferson Opens New Familial Colorectal Cancer Registry

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Related Content
27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

27 Elacestrant vs Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer With ESR1-Mutated Tumors: ESR1 Allelic Frequencies and Clinical Activity From the Phase 3 EMERALD Trial

Aditya Bardia, MD, MPH;Javier Cortés, MD;Francois Clement Bidard;Guillermo Streich;José García-Sáenz;Janice Lu, MD, PhD ;Giulia Tonini;Simona Scartoni;Alessandro Paoli;Alessio Fiascarelli;Alessandro Bressan;Monica Binaschi;Tomer Wasserman;Virginia Kaklamani, MD, DSc
June 19th 2025
Article
PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.

BGB-16673 antitumor activity occurred particularly among patients with BTK-resistant mutations and those refractory to prior cBTK and ncBTK inhibition.

BGB-16673 Shows Tolerability, Activity in Waldenström Macroglobulinemia

Roman Fabbricatore
June 19th 2025
Article

BGB-16673 antitumor activity occurred particularly among patients with BTK-resistant mutations and those refractory to prior cBTK and ncBTK inhibition.

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
June 16th 2025
Podcast

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

First-Line Radiotherapy Combo May Show Benefit in Oligoprogressive HCC

First-Line Radiotherapy Combo May Show Benefit in Oligoprogressive HCC

Tim Cortese
June 19th 2025
Article

First-line systemic therapy plus radiation therapy improved PFS vs second-line systemic therapy with or without radiation in hepatocellular carcinoma.

Data from the 2025 EHA Congress show developments in novel therapeutic strategies across different multiple myeloma, leukemia, and lymphoma populations.

EHA 2025: Top 5 Takeaways for Hematologic Malignancy Management

Russ Conroy
June 18th 2025
Article

Data from the 2025 EHA Congress show developments in novel therapeutic strategies across different multiple myeloma, leukemia, and lymphoma populations.